{"product_id":"real-world-data-rwd-by-source-emr-claims-pharmacy-disease-registries-application-market-access-drug-development-approvals-oncology-neurology-post-market-surveillance-and-end-user-pharma-payers-providers-global-forecast-to-2029","title":"Real-world Data (RWD) by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development \u0026 Approvals (Oncology, Neurology), Post Market Surveillance], and End User (Pharma, Payers, Providers) - Global Forecast to 2029","description":"\u003cp\u003eReal-world Data (RWD) by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development \u0026amp; Approvals (Oncology, Neurology), Post Market Surveillance], and End User (Pharma, Payers, Providers) - Global Forecast to 2029\u003c\/p\u003e\n\n\u003cp\u003eReal-world Data (RWD) by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development \u0026amp; Approvals (Oncology, Neurology), Post Market Surveillance], and End User (Pharma, Payers, Providers) - Global Forecast to 2029\u003c\/p\u003e\n\n\u003cp\u003eThe real-world data (RWD) market is expected to grow at a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029.\u003c\/p\u003e\n\n\u003cp\u003eFollowing a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the real-world data (RWD) market.\u003c\/p\u003e\n\n\u003cp\u003eThe growing burden of chronic diseases, delays in drug development and the consequent increase in development costs, the rising attention towards personalized healthcare, the shift toward value-based care, and rapidly growing big data in the healthcare sector are the major drivers for the real-world data (RWD) market. However, the lack of standardized methodologies for developing real-world data solutions is a major challenge for market growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on source, the pharmacy data segment is slated to register the CAGR during the forecast period. The increasing focus on e-prescriptions and the volume of pharmacy data can serve as real-world data sources to help guide sales and market access strategy, provide data-driven insights to aid the payers' and HTAs' decision-making, maximize payer coverage, and improve patient outcomes.\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the drug development \u0026amp; approvals segment is slated to register the highest CAGR during the forecast period. RWD can be applied in drug development to support label expansion, optimize clinical use to support label revisions and meet postmarketing information and safety monitoring requirements. RWD insights can help accelerate the drug development \u0026amp; approvals process in a manner aligned with the interests of all stakeholders. Thus, the effective deployment of RWD can accelerate the pace of discovery, enable drug approvals, and help understand the impact of new therapies, thereby boosting the market's growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the pharmaceutical, biotechnology, and medical device companies segment is slated to register the highest CAGR during the forecast period. The increasing importance of real-world data studies in drug development \u0026amp; approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are driving the growth of this segment.\u003c\/p\u003e\n\n\u003cp\u003eBased on geography, North America is expected to grow with the highest CAGR during the forecast period. The growth of this regional market is attributed to the increasing prevalence of chronic diseases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, availability of electronic datasets, the region’s well-developed healthcare industry, and the increasing utilization of big data in healthcare.\u003c\/p\u003e\n\n\u003cp\u003eSome of the key companies operating in the global RWD market are Elevance Health, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report:\u003c\/p\u003e\n\n\u003cp\u003eGlobal Real-world Data Market, by Source\u003c\/p\u003e\n\n\u003cp\u003eEMR\/EHR\/Clinical Data\u003cbr\u003e\nClaims \u0026amp; Billing Data\u003cbr\u003e\nPharmacy Data\u003cbr\u003e\nProduct\/Disease Registries Data\u003cbr\u003e\nGenomics Data\u003cbr\u003e\nOther Datasets\u003c\/p\u003e\n\n\u003cp\u003eNote: Other sources include data gathered from other sources, such as mobile devices, wearable devices, and social media, which can provide information on health status.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Real-world Data Market, by Application\u003c\/p\u003e\n\n\u003cp\u003eMarket Access \u0026amp; Reimbursement\/Coverage Decisions\u003cbr\u003e\nDrug Development \u0026amp; Approvals\u003cbr\u003e\nOncology\u003cbr\u003e\nNeurology\u003cbr\u003e\nImmunology\u003cbr\u003e\nCardiovascular Diseases\u003cbr\u003e\nOther Therapeutic Areas\u003cbr\u003e\nPost-market Surveillance\u003cbr\u003e\nMedical Device Development \u0026amp; Approvals\u003cbr\u003e\nRegulatory and Clinical Decision-making\u003c\/p\u003e\n\n\u003cp\u003eNote: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Real-world Data Market, by End User\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical, Biotechnology, and Medical Device Companies\u003cbr\u003e\nHealthcare Payers\u003cbr\u003e\nHealthcare Providers\u003cbr\u003e\nOther End Users\u003c\/p\u003e\n\n\u003cp\u003eNote: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Real-world Data Market, by Geography\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nU.K.\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe (RoE)\u003cbr\u003e\nAsia-Pacific (APAC)\u003cbr\u003e\nJapan\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nTaiwan\u003cbr\u003e\nSingapore\u003cbr\u003e\nRest of APAC (RoAPAC)\u003cbr\u003e\nLatin America\u003cbr\u003e\nMiddle East \u0026amp; Africa Real-World Data (RWD) Market - Report Summary   Report Metrics Details   Years Considered 2020 - 2029   Base Year 2021   Forecast Period 2022-2029   Page Count 203   Units Referenced Value (USD Million)   Segments\/Key Topics Market by Source, Market by Application, Market by End User, Market by Geography   Regions Covered North America, Europe, Asia-Pacific, Latin America , and Middle East \u0026amp; Africa  Key Companies Mentioned Key Companies Mentioned\tElevance Health, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).\u003c\/p\u003e   \n\n \u003cp\u003eFAQs About the Report\u003c\/p\u003e \n\n\u003cp\u003eWhat is the value of revenue generated from the RWD across the globe? At what rate their demand expected to grow for the next 5-7 years?\u003c\/p\u003e \n\n\u003cp\u003eThe global RWD market is projected to reach $1.66 billion by 2029, at a CAGR of 7.4%% during the forecast period.\u003c\/p\u003e \n\n\u003cp\u003eWhich source type is estimated to hold the major share of the market?\u003c\/p\u003e \n\n\u003cp\u003eBased on source, the EMR\/EHR\/clinical data segment is expected to account for the largest share of the global real-world data (RWD) market in 2022. Real-world data is data from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Analyzing the collected data generates real-world evidence, which, in turn, helps in retrospective studies and provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. EHRs are the most commonly used form of healthcare database. Electronic health records (EHR)\/electronic medical record (EMR)\/clinical data include data gathered from various clinical data sources that enable clinical decision-making, improved patient outcomes, and drug safety and effectiveness. These factors drive the growth of this segment.\u003c\/p\u003e \n\n\u003cp\u003eWhich application segment of the market is projected to create more traction in the RWD market?\u003c\/p\u003e \n\n\u003cp\u003eBased on application, the drug development \u0026amp; approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data to enhance drug discovery and development, and increasing investments by biopharmaceutical companies in R\u0026amp;D. In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The real-world data is regularly utilized to inform aspects of drug development. The adoption of AI in drug development \u0026amp; approval processes is also driving the demand for RWD. AI integrated RWD studies are conducted in various stages of drug development process such as for designing clinical trials; modeling and forecasting patient enrichment and recruitment using multiple RWD sources; selecting investigator site; patient monitoring \u0026amp; managing and medication adherence \u0026amp; retention; market access; and post-market surveillance\u003c\/p\u003e \n\n\u003cp\u003eWhat are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global RWD market?\u003c\/p\u003e \n\n\u003cp\u003eThe growing burden of chronic diseases, delays in drug development and the consequent increase in development costs, the rising attention towards personalized healthcare, the shift toward value-based care, and rapidly growing big data in the healthcare sector are the major drivers for the real-world data (RWD) market. In addition, emerging markets and rising focus on end-to-end RWE services are some of the factors expected to offer significant growth opportunities for players operating in the RWD market.\u003c\/p\u003e \n\n\u003cp\u003eWho are the major players operating in the global RWD market?\u003c\/p\u003e \n\n\u003cp\u003eKey companies operating in the global RWD market are Elevance Health, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).\u003c\/p\u003e \n\n\u003cp\u003eWhich regions\/countries are expected to offer significant growth opportunities for the companies operating in RWD market?\u003c\/p\u003e \n\n\u003cp\u003eThe emerging economies like Japan and China based in Asia are projected to offer significant growth opportunities for the companies in this market during the forecast period of 2022–2029. Growing demand for data defining the value and effectiveness of medicines by payers, growing demand for RWD studies in drug R\u0026amp;D, and increasing government interest in using real-world studies for regulatory decision-making are the factors that will offer significant growth opportunities in this region.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ - \/ MCW16225341","offer_id":47645277880626,"sku":null,"price":5010.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/real-world-data-rwd-by-source-emr-claims-pharmacy-disease-registries-application-market-access-drug-development-approvals-oncology-neurology-post-market-surveillance-and-end-user-pharma-payers-providers-global-forecast-to-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}